Biotech funds spring like mushrooms in Singapore

Singapore is capturing the attention of biotech fund managers who are competing for the island-state''s investors.
September 08, 2000
Singapore investors seeking to gamble on biotechnology stocks are suddenly spoilt for choice of investment vehicles.

Just two months ago there were no dedicated biotech funds in Singapore. Now there are three. First came Franklin Templeton Investments and Dresdner Asset Management. This week UBS Asset Management joined the fray with its UBS (SG) Investment Fund-Biotech. Others, such as Polaris Asset Management are also gearing up to launch Asian biotechnology funds.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media